EKF.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Stats
Šios dienos apimtis	82 356.00
Vidutinė apimtis	310 977
Rinkos kapitalizacija	125.23M
EPS	£0 ( 2024-03-25 )
Last Dividend	£1.200 ( 2022-11-02 )
Next Dividend	£0 ( N/A )
P/E	27.60
ATR14	£0 (0.00%)

EKF Diagnostics Holdings Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MPL.L	0.932
PDL.L	0.924
TPX.L	0.923
OMIP.L	0.916
RDT.L	0.913
SCLP.L	0.913
3SNV.L	0.909
TBLD.L	0.909
3SUB.L	0.906
DSW.L	0.902

10 Labiausiai neigiamai susiję koreliacijos
AEXG.L	-0.959
EMR.L	-0.958
CFX.L	-0.957
INSE.L	-0.949
SPEC.L	-0.939
VAST.L	-0.939
SKL.L	-0.938
NWT.L	-0.934
IPF.L	-0.932
GRA.L	-0.926

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

EKF Diagnostics Holdings Finansinės ataskaitos

Annual	2023
Pajamos:	£52.61M
Bruto pelnas:	£24.44M (46.45 %)
EPS:	£0.00520

FY	2023
Pajamos:	£52.61M
Bruto pelnas:	£24.44M (46.45 %)
EPS:	£0.00520

FY	2022
Pajamos:	£66.64M
Bruto pelnas:	£24.04M (36.07 %)
EPS:	£-0.0209

FY	2021
Pajamos:	£81.84M
Bruto pelnas:	£39.37M (48.10 %)
EPS:	£0.0347

Financial Reports:

No articles found.

EKF Diagnostics Holdings Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£1.200 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

EKF Diagnostics Holdings Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.77 - good (97.65%) | Divividend Growth Potential Score: 5.31 - Stable (6.15%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£1.000	2020-11-04
Last Dividend	£1.200	2022-11-02
Next Dividend	£0	N/A
Payout Date	2022-12-01
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	£3.30	--
Avg. Dividend % Per Year	0.73%	--
Score	3.09	--
Div. Sustainability Score	9.77
Div.Growth Potential Score	5.31
Div. Directional Score	7.54	--

Next Divdend (Est)
(2024-09-30)

£0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.09

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2020	£1.000	2.98%
2021	£1.100	1.62%
2022	£1.200	1.58%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
BBOX.L	Dividend King	2023-08-10	Quarterly	11	2.62%
VTU.L	Dividend Knight	2023-06-29	Annually	14	1.47%
MUL.L	Ex Dividend Junior	2023-10-26	Sporadic	29	0.20%
DUKE.L	Dividend King	2023-09-28	Quarterly	8	3.65%
SMJ.L	Dividend Knight	2023-05-04	Semi-Annually	33	1.30%
INVP.L	Dividend King	2023-08-17	Annually	23	3.82%
BRCK.L	Dividend Knight	2023-08-24	Semi-Annually	6	2.38%
PAGE.L	Dividend Knight	2023-08-31	Annually	24	3.53%
FERG.L	Dividend Knight	2023-06-15	Semi-Annually	32	1.37%
0KEZ.L	Dividend Junior	2023-09-22	Sporadic	7	0.78%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0447	1.500	9.11	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0291	1.200	9.03	10.00	[0 - 0.3]
returnOnEquityTTM	0.0358	1.500	-0.713	-1.070	[0.1 - 1]
payoutRatioTTM	2.32	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	2.69	0.800	1.545	1.236	[1 - 3]
quickRatioTTM	1.768	0.800	4.31	3.45	[0.8 - 2.5]
cashRatioTTM	0.814	1.500	6.59	9.89	[0.2 - 2]
debtRatioTTM	0.0507	-1.500	9.16	-10.00	[0 - 0.6]
interestCoverageTTM	63.41	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.0139	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.00146	2.00	-0.000732	-0.00146	[0 - 20]
debtEquityRatioTTM	0.0611	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.464	1.000	5.59	5.59	[0.2 - 0.8]
operatingProfitMarginTTM	0.0904	1.000	-0.192	-0.192	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.540	1.000	2.56	2.56	[0.2 - 2]
assetTurnoverTTM	0.651	0.800	9.00	7.20	[0.5 - 2]
Total Score				9.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	53.24	1.000	4.72	0	[1 - 100]
returnOnEquityTTM	0.0358	2.50	-0.458	-1.070	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00146	2.00	-0.000488	-0.00146	[0 - 30]
dividendYielPercentageTTM	4.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0139	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	2.32	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	53.24	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.120	1.000	9.50	0	[0.1 - 0.5]
Total Score				5.31

EKF Diagnostics Holdings

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.